Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results

被引：0
|
作者：
Muggia, F. M. [1 ,2 ]
Boyd, L. [1 ,2 ]
Liebes, L. [1 ,2 ]
Downey, A. [1 ,2 ]
Muller, C. [1 ,2 ]
Pothuri, B. [1 ,2 ]
Blank, S. [1 ,2 ]
Rutledge, T. [1 ,2 ]
Fishman, D. [1 ,2 ]
Verschraegen, C. [1 ,2 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] Univ New Mexico, Albuquerque, NM 87131 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5548
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC).
    Muggia, F.
    Safra, T.
    Borgato, L.
    Gandhi, A.
    Mancinc, G.
    Gabizon, A.
    Liebes, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Efficacy and safety of generic pegylated liposomal doxorubicin (PLD) in relapsed ovarian cancer
    Ghosh, I.
    Dwary, A.
    Dabkara, D.
    Bhaumik, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S731 - S731
  • [3] Relationship between serum hormone levels and pharmacokinetics (PK) of PEGylated liposomal doxorubicin (PLD) in patients with refractory ovarian cancer
    Kumar, Parag
    Caron, Whitney P.
    Song, Gina
    Gallagher, Katie
    Clarke-Pearson, Daniel L.
    Brewster, Wendy R.
    Van Le, Linda
    Bae-Jump, Victoria
    Gehrig, Paola A.
    Zamboni, William C.
    CANCER RESEARCH, 2012, 72
  • [4] A phase II study of pegylated liposomal doxorubicin (PLD), and cyclophosphamide (CTX) as second line therapy in platinum resistant ovarian cancer (OC) patients
    Montesinos, J.
    Losa, F.
    Gallego, O.
    Eres, N.
    Balil, A.
    Franquesa, R.
    Gonzalez, S.
    Cirera, J.
    ANNALS OF ONCOLOGY, 2004, 15 : 130 - 130
  • [5] Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC)
    Vergote, I.
    Finkler, N. J.
    Hall, J. B.
    Melnyk, O.
    Edwards, R. P.
    Jones, M.
    Meng, L.
    Brown, G. L.
    Rankin, E. M.
    Burke, J. J., II
    Rose, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] A RANDOMIZED PHASE III STUDY OF TRABECTEDIN WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) VERSUS PLD IN RELAPSED, RECURRENT OVARIAN CANCER (OC)
    Monk, B. J.
    Herzog, T.
    Kaye, S.
    Krasner, C. N.
    Vermorken, J.
    Muggia, F.
    Pujade-Lourraine, E.
    Renshaw, F. G.
    Lebedinsky, C.
    Poveda, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 2 - 2
  • [7] Pegylated liposomal doxorubicin with bevacizumab in the treatment of platinum-resistant ovarian cancer: Toxicity profile results
    Czok, S.
    Jewell, A.
    Shawki, S.
    Boyd, L.
    Smith, H.
    Blank, S.
    Muller, C.
    Verschraegen, C.
    Muggia, F.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S83 - S83
  • [8] Implications of BRCA mutations on recurrent ovarian cancer outcome treated with pegylated liposomal doxorubicin (PLD)
    Safra, Tamar
    Borgato, Lucia
    Nicoletto, Maria Ornella
    Donach, Martin Edward
    Rolnitzky, Linda
    Geva, Ravit
    Peles, Sharon
    Pua, Thara
    Novetsky, Akiva
    Gabizon, Alberto
    Muggia, Franco
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [9] A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma
    Valerio, MR
    Tagliaferri, P
    Raspagliesi, F
    Fulfaro, F
    Badalamenti, G
    Arcara, C
    Cicero, G
    Russo, A
    Venuta, S
    Guarneri, G
    Gebbia, N
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 : 79 - 85
  • [10] Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation
    Main, C
    Bojke, L
    Griffin, S
    Norman, G
    Barbieri, M
    Mather, L
    Stark, D
    Palmer, S
    Riemsma, R
    HEALTH TECHNOLOGY ASSESSMENT, 2006, 10 (09) : 1 - +
12345